Last reviewed · How we verify
Leticia Maria Defendi Barboza Marson — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Testosterone cypionate (200mg/3ml) | Testosterone cypionate (200mg/3ml) | marketed | Androgenic steroid | Androgen receptor | Oncology |
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Leticia Maria Defendi Barboza Marson:
- Leticia Maria Defendi Barboza Marson pipeline updates — RSS
- Leticia Maria Defendi Barboza Marson pipeline updates — Atom
- Leticia Maria Defendi Barboza Marson pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Leticia Maria Defendi Barboza Marson — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/leticia-maria-defendi-barboza-marson. Accessed 2026-05-17.